Why the previous drug matters more than the drug name
Targeted cancer treatment acts on particular molecular features of a tumour. Biomarker findings can help clinicians assess potential treatment options. That means a drug name on its own tells a specialist very little: the same drug may be used in different cancers, at different stages, with different biomarker results behind it.
For an overseas patient, the practical question is not "can I get drug X in China?" It is "does my previous treatment history, together with my current biomarker and pathology information, give a Chinese centre enough to assess whether any targeted option is relevant now?" Those are different questions, and only the second one is answerable from records.
This is why the first useful step is not booking travel. It is confirming which drug you took, why it was chosen, and what happened while you were on it. Without that, a centre is being asked to guess.
The records that let a centre assess prior targeted treatment
A specialist reviewing your case will want the treatment story in sequence, not a pile of unrelated scans. The most useful starting point is the pathology report that confirmed the diagnosis, including any biomarker or molecular testing that was performed and the result. If a biomarker test was done, the report itself matters, not a summary in a discharge letter.
Next comes the drug history. For each targeted therapy you have received, the treating team needs the drug name, the start and stop dates, the dose, and the reason it stopped. "It stopped working" and "I could not tolerate it" lead to very different clinical discussions. If treatment was paused, reduced or switched, that detail belongs in the summary.
Response information is equally important. Which scans were done before and during treatment, and what did the reports say? If the tumour shrank, stayed stable or progressed, the imaging and the reports that recorded this are the evidence. Blood tests, tumour marker trends and any adverse events also help.
Finally, the current picture: the most recent imaging, the latest blood results, current symptoms, current medicines and any other treatment received since the targeted drug, including chemotherapy, immunotherapy, radiotherapy or surgery. A centre assessing a next step needs to know what has already been tried and what the disease is doing now.
- Pathology report confirming the diagnosis, with any biomarker or molecular test results
- For each previous targeted drug: name, dates, dose, reason for stopping
- Imaging reports before, during and after that treatment, plus the most recent scan
- Recent blood tests and any relevant tumour marker results
- Current medicines, symptoms and any treatment received since the targeted drug
Biomarker context: what to confirm before asking about options
Targeted therapy is linked to molecular features, so the biomarker question is central. But it is easy to over-read a report. A biomarker result does not automatically mean a particular drug is suitable, and not every finding is actionable. Whether a specific result points to a specific option is a clinical judgement that depends on the cancer type, the stage, prior treatments and the current situation.
This is why patients should avoid arriving with a self-made list of drugs matched to a mutation. A more useful approach is to ask the centre a precise question: given this diagnosis, this biomarker result and this prior treatment history, is there a targeted option the team would consider assessing, and what further information would they need?
If molecular testing was never done, or was done some time ago on older tissue, that is a question for the treating clinician, not something to resolve by ordering tests independently. Whether new testing is appropriate, and what type, depends on the individual case. Ask the centre what it would require before any decision about testing.
What a Chinese centre can and cannot confirm from records
A records-based review can help a specialist understand your history and give an opinion on whether the case is worth assessing further. It cannot confirm hospital acceptance, final eligibility for a particular treatment, or that a specific drug is available and appropriate for you. Those decisions belong to the treating hospital and its clinicians after they have the information they need.
It is also worth separating two ideas that patients often merge. A review of your records is not the same as being accepted for treatment. An initial enquiry is not a commitment to travel, and it does not require buying a proxy consultation. The hospital decides suitability, and that decision comes after a proper clinical assessment.
So the honest framing is this: a Chinese centre may be able to assess your case, but whether it can offer a relevant targeted option, and under what conditions, is something only that centre can answer after reviewing your records. Ask directly rather than assuming.
Questions to ask about continuing treatment and monitoring
If you are currently on a targeted drug, the practical concern is continuity. You need to know how a transition would work: whether the same drug could be continued, whether monitoring would follow the same schedule, and how any side effects would be managed. These are not administrative details; they affect safety.
Ask the centre how it would handle ongoing treatment and monitoring if you were accepted as a patient. Ask what records it needs to assess continuation, and what would happen if the drug you take is not part of its usual practice. Ask who would be responsible for dose decisions and follow-up tests, and how results would be communicated to you and to your current team.
It also helps to ask what the centre would need from your present clinician. A clear handover of treatment history, current dose and monitoring plan reduces the risk of gaps. You do not need to resolve these questions yourself; you need to know which ones the centre will answer before you commit to anything.
- Could the current targeted drug be continued, and under what conditions?
- How would monitoring and follow-up tests be arranged and communicated?
- Who would manage dose decisions and side effects?
- What information would the centre need from your current treating team?
How to prepare a first enquiry without overloading it
A first enquiry does not need your complete medical archive. It needs enough to let a coordinator understand the diagnosis, the previous targeted drug and the main question. A short summary with the cancer type, the drug name and dates, the reason it stopped, and what you want to know is usually enough to identify the relevant next step.
From there, the centre can tell you what records it wants and how to share them securely. Do not send passport numbers, card details or a full archive at the first contact. If you are currently unwell or your symptoms are worsening, seek local medical care first; an overseas enquiry should not delay necessary assessment.
The next step is straightforward: send a brief summary of your diagnosis, previous targeted treatment and current question through the enquiry form. An initial case review is free and does not commit you to a proxy consultation or to travel. The centre will tell you what it can assess and what it needs next.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.